9/24/2019 | HY | Moody’s changes view on Solveig’s ratings to negative
|
9/17/2014 | PP | Aastrom greenshoe exercised in $40.25 million public stock sale
|
9/11/2014 | PP | Aastrom prices $35 million public offering of stock at $2.55 per share
|
8/6/2014 | PP | Aastrom Biosciences aims to price public offering of its common stock
|
6/27/2014 | PP | Aastrom arranges $3.8 million at-the-market issuance sales agreement
|
1/27/2014 | PP | Aastrom Biosciences may raise $15 million via stock purchase agreement
|
12/2/2013 | PP | Aastrom renews $15.9 million at-the-market issuance sales agreement
|
8/16/2013 | PP | Aastrom greenshoe partially exercised for $9 million public stock sale
|
8/13/2013 | PP | Aastrom Biosciences prices $8.7 million public sale of stock at $0.30
|
8/12/2013 | PP | Aastrom Biosciences will sell units, not stock, in its public offering
|
8/8/2013 | PP | Aastrom names co-lead manager for $15 million public offering of stock
|
7/25/2013 | PP | Aastrom reduces public offering of common stock to $15 million
|
4/29/2013 | PP | Aastrom Biosciences will price a public offering of its common stock
|
3/9/2012 | PP | Aastrom Biosciences seals $40 million private placement of preferreds
|
6/16/2011 | CVHYPF | Aastrom files $100 million shelf covering stock, debt and preferreds
|
11/12/2010 | CVHYPF | Aastrom files $75 million shelf covering stock, debt and preferreds
|
11/26/2008 | CV | Aastrom files $50 million shelf
|
10/29/2008 | PP | New Issue: Aastrom arranges $15 million equity financing facility with Fusion
|
10/16/2007 | PP | New Issue: Aastrom arranges $13.5 million direct placement of units
|
10/16/2007 | PP | Market Commentary: CGX Energy to raise $30 million, TGX World Energy announces C$12 million deal
|
11/8/2006 | BT | Market Commentary: Catalyst higher on debut; Hollis-Eden off 19% on PIPE; stem cell names better; Trimeris rises 23%
|
9/15/2006 | BT | Aastrom says tissue repair cells effective in long bone fractures
|
9/13/2006 | BT | Aastrom's cash reaches $43 million, R&D expenses increase in Q4
|
8/29/2006 | BT | Market Commentary: Teva lower; Endo, Penwest up; StemCells gains 7%; Nastech higher; Hemispherx rises 11%
|
6/29/2006 | BT | Aastrom achieves U.S. bone fracture milestone
|
6/29/2006 | BT | Market Commentary: Invitrogen, Geron rise on pact; other stem cell names higher; Keryx up 8%; Nabi up over 2%
|
5/10/2006 | BT | Aastrom receives manufacturing license at facility for production of stem cell products
|
4/6/2006 | BTPP | New Issue: Aastrom Biosciences secures $25.51 million from direct placement of stock
|
4/6/2006 | PP | Market Commentary: Oscient Pharmaceuticals gears up to wrap $34.74 million PIPE; Aastrom secures $25.51 million
|
3/23/2006 | BT | Aastrom gets orphan drug designation for proprietary bone marrow cells
|
3/22/2006 | BT | Aastrom: Trial of TRCs with stem cells to treat severe fractures shows positive bone regeneration
|
3/20/2006 | BT | Orthovita, Aastrom Biosciences collaborate for orthopedic products
|
12/21/2005 | BT | Aastrom study shows its Tissue Repair Cells help bone growth for dental implants
|
12/13/2005 | BT | Aastrom begins phase 1/2 study of Tissue Repair Cells for bone fractures
|
11/30/2005 | BT | Aastrom begins phase 1, 2 trial of Tissue Repair Cell's ability to form new bone tissue in spine
|
7/29/2005 | BT | Market Commentary: Advanced Life Sciences, Avalon IPOs delayed; ZymoGenetics on deck for Wed; stem cell names rise
|
7/18/2005 | BT | Market Commentary: Momenta off on secondary sale; Geron zooms on Merck pact; ViroPharma up; Amgen quiet
|
6/17/2005 | BT | Market Commentary: Mylan Labs bond deal surfaces; Vertex up, Merck lags; Genentech rises; stem cell names watched
|
3/24/2005 | CV | Aastrom Biosciences files $50 million shelf
|
1/13/2005 | PP | New Issue: Aastrom Biosciences closes final tranche of private placement for $12 million
|
1/13/2005 | PP | Market Commentary: Private placement volume remains weak; Moscow CableCom closes $51 million deal
|